KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares RepurchasedShort-Term Debt repayments
Ratios

Emergent BioSolutions (EBS) Receivables Refunds (2016 - 2020)

Emergent BioSolutions (EBS) has 11 years of Receivables Refunds data on record, last reported at $10.2 million in Q1 2020.

  • For Q1 2020, Receivables Refunds changed N/A year-over-year to $10.2 million; the TTM value through Mar 2020 reached $10.2 million, changed N/A, while the annual FY2019 figure was $4.6 million, 46.51% down from the prior year.
  • Receivables Refunds reached $10.2 million in Q1 2020 per EBS's latest filing, up from $4.6 million in the prior quarter.
  • Across five years, Receivables Refunds topped out at $11.8 million in Q3 2016 and bottomed at $2.4 million in Q4 2017.
  • Average Receivables Refunds over 5 years is $7.3 million, with a median of $7.0 million recorded in 2018.
  • Peak YoY movement for Receivables Refunds: tumbled 77.85% in 2016, then skyrocketed 258.33% in 2018.
  • A 5-year view of Receivables Refunds shows it stood at $10.0 million in 2016, then crashed by 75.99% to $2.4 million in 2017, then surged by 258.33% to $8.6 million in 2018, then plummeted by 46.51% to $4.6 million in 2019, then surged by 121.74% to $10.2 million in 2020.
  • Per Business Quant database, its latest 3 readings for Receivables Refunds were $10.2 million in Q1 2020, $4.6 million in Q4 2019, and $8.6 million in Q4 2018.